Roche's Divarasib Outperforms Approved Rivals in Phase III Lung Cancer Trial

• Roche's Genentech will present cancer trial results at the ESMO annual meeting in Madrid on October 23-27, 2026.
• Phase III Krascendo 1 results showed divarasib outperformed sotorasib or adagrasib in previously treated KRAS G12C-mutated advanced lung cancer.
• Patient-reported lidERA results suggest giredestrant's improved efficacy over endocrine therapy did not compromise tolerability or health-related quality of life.
• Tam-Peli presentations will include interim Phase III results comparing the drug with chemotherapy in heavily pretreated recurrent or metastatic nasopharyngeal cancer.
• Previously presented Phase III TAISHAN-302 results showed Tam-Peli met survival, disease-progression and tumor-response endpoints in second-line small cell lung cancer.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Roche Holding AG published the original content used to generate this news brief via Business Wire (Ref. ID: 20261018339341) on October 19, 2026, and is solely responsible for the information contained therein.